For spinal fusions and the treatment of non-union fractures, biological substrates, scaffolds, or carriers often are applied as a graft to support regeneration of bone. The selection of an appropriate material critically influences cellular function and, ultimately, patient outcomes. Human bone marrow mesenchymal stem cells (BMSCs) are regarded as a critical component of bone healing. However, the interactions of BMSCs and commercial bone matrices are poorly reported. BMSCs were cultured with several commercially available bone substrates (allograft, demineralized bone matrix (DBM), collagen, and various forms of calcium phosphates) for 48 h to understand their response to graft materials during surgical preparation and the first days following implantation (cell retention, gene expression, pH). At 30 and 60 min, bone chips and inorganic substrates supported significantly more cell retention than other materials, while collagen-containing materials became soluble and lost their structure. At 48 h, cells bound to β-tricalcium phosphate-hydroxyapatite (βTCP-HA) and porous hydroxyapatite (HA) granules exhibited osteogenic gene expression statistically similar to bone chips. Through 24 h, the DBM strip and βTCP-collagen became mildly acidic (pH 7.1–7.3), while the DBM poloxamer-putties demonstrated acidity (pH < 5) and the bioglass-containing carrier became basic (pH > 10). The dissolution of DBM and collagen led to a loss of cells, while excessive pH changes potentially diminish cell viability and metabolism. Extracts from DBM-poloxamers induced osteogenic gene expression at 48 h. This study highlights the role that biochemical and structural properties of biomaterials play in cellular function, potentially enhancing or diminishing the efficacy of the overall therapy.
References
[1]
Burstein, F.D. Bone substitutes. Cleft Palate Craniofac. J. 2000, 37, 1–4, doi:10.1597/1545-1569(2000)037<0001:ESNTIT>2.3.CO;2.
[2]
Shegarfi, H.; Reikeras, O. Review article: Bone transplantation and immune response. J. Orthop. Surg. 2009, 17, 206–211.
[3]
Kao, S.T.; Scott, D.D. A review of bone substitutes. Oral Maxillofac. Surg. Clin. North Am. 2007, 19, 513–521, doi:10.1016/j.coms.2007.06.002.
[4]
Aro, H.T.; Aho, A.J. Clinical use of bone allografts. Ann. Med. 1993, 25, 403–412, doi:10.3109/07853899309147303.
[5]
Albrektsson, T. In vivo studies of bone grafts. The possibility of vascular anastomoses in healing bone. Acta Orthop. Scand. 1980, 51, 9–17, doi:10.3109/17453678008990763.
[6]
De Boer, H.H. The history of bone grafts. Clin. Orthop. Relat. Res. 1988, 226, 292–298.
[7]
Faour, O.; Dimitriou, R.; Cousins, C.A.; Giannoudis, P.V. The use of bone graft substitutes in large cancellous voids: Any specific needs? Injury 2011, 42, S87–S90, doi:10.1016/j.injury.2011.06.020.
[8]
Dimitriou, R.; Jones, E.; McGonagle, D.; Giannoudis, P.V. Bone regeneration: Current concepts and future directions. BMC Med. 2011, 9, 66, doi:10.1186/1741-7015-9-66.
[9]
Derubeis, A.R.; Cancedda, R. Bone marrow stromal cells (BMSCs) in bone engineering: Limitations and recent advances. Ann. Biomed. Eng. 2004, 32, 160–165, doi:10.1023/B:ABME.0000007800.89194.95.
[10]
Garg, T.; Singh, O.; Arora, S.; Murthy, R.S.R. Scaffold: A novel carrier for cell and drug delivery. Crit. Rev. Ther. Drug Carr. Syst. 2012, 29, 1–63, doi:10.1615/CritRevTherDrugCarrierSyst.v29.i1.10.
[11]
Zhang, Z. Bone regeneration by stem cell and tissue engineering in oral and maxillofacial region. Fron. Med. 2011, 5, 401–413, doi:10.1007/s11684-011-0161-7.
[12]
Chimutengwende-Gordon, M.; Khan, W.S. Advances in the use of stem cells and tissue engineering applications in bone repair. Curr. Stem Cell Res. Ther. 2012, 7, 122–126, doi:10.2174/157488812799219036.
[13]
Prockop, D.J. Further proof of the plasticity of adult stem cells and their role in tissue repair. J. Cell Biol. 2003, 160, 807–809, doi:10.1083/jcb.200302117.
[14]
Prockop, D.J. Adult stem cells gradually come of age. Nat. Biotechnol. 2002, 20, 791–792, doi:10.1038/nbt0802-791.
[15]
Prockop, D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276, 71–74, doi:10.1126/science.276.5309.71.
[16]
Phinney, D.G.; Prockop, D.J. Concise review: Mesenchymal stem/multipotent stromal cells: The state of transdifferentiation and modes of tissue repair—Current views. Stem Cells 2007, 25, 2896–2902, doi:10.1634/stemcells.2007-0637.
[17]
Gregory, C.A.; Prockop, D.J.; Spees, J.L. Non-hematopoietic bone marrow stem cells: Molecular control of expansion and differentiation. Exp. Cell Res. 2005, 306, 330–335, doi:10.1016/j.yexcr.2005.03.018.
[18]
Gregory, C.A.; Gunn, W.G.; Reyes, E.; Smolarz, A.J.; Munoz, J.; Spees, J.L.; Prockop, D.J. How Wnt signaling affects bone repair by mesenchymal stem cells from the bone marrow. Ann. N. Y. Acad. Sci. 2005, 1049, 97–106, doi:10.1196/annals.1334.010.
[19]
Gregory, C.A.; Prockop, D.J. Fundementals of Culture and Characterization of Mesenchymal Stem/Progenitor Cells from Bone Marrow Stroma. In Culture of Human Stem Cells; Ian Freshney, R., Stacey, G.N., Auerbach, J.M., Eds.; Wiley-Liss: Hoboken, NJ, USA, 2007; Volume 208, doi:10.1002/9780470167526.ch9.
[20]
Pittenger, M.F. Mesenchymal stem cells from adult bone marrow. Methods Mol. Biol. 2008, 449, 27–44.
[21]
Pittenger, M.; Vanguri, P.; Simonetti, D.; Young, R. Adult mesenchymal stem cells: Potential for muscle and tendon regeneration and use in gene therapy. J. Musculoskelet. Neur. Interact. 2002, 2, 309–320.
[22]
Pittenger, M.F.; Martin, B.J. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 2004, 95, 9–20, doi:10.1161/01.RES.0000135902.99383.6f.
Caplan, A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell. Physiol. 2007, 213, 341–347, doi:10.1002/jcp.21200.
[25]
Caplan, A.I.; Bruder, S.P. Mesenchymal stem cells: Building blocks for molecular medicine in the 21st century. Trends Mol. Med. 2001, 7, 259–264, doi:10.1016/S1471-4914(01)02016-0.
[26]
Caplan, A.I.; Goldberg, V.M. Principles of tissue engineered regeneration of skeletal tissues. Clin. Orthop. Relat. Res. 1999, 367, S12–S16, doi:10.1097/00003086-199910001-00003.
[27]
Zomorodian, E.; Eslaminejad, M.B. Mesenchymal stem cells as a potent cell source for bone regeneration. Stem Cells Int. 2012, 2012, doi:org/10.1155/2012/980353.
[28]
Sakaguchi, Y.; Sekiya, I.; Yagishita, K.; Ichinose, S.; Shinomiyaet, K.; Muneta, T. Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. Blood 2004, 104, 2728–2735, doi:10.1182/blood-2003-12-4452.
[29]
Yoshimura, H.; Muneta, T.; Nimura, A.; Yokoyama, A.; Koga, H.; Sekiya, I. Comparison of rat mesenchymal stem cells derived from bone marrow, synovium, periosteum, adipose tissue, and muscle. Cell Tissue Res. 2007, 327, 449–462, doi:10.1007/s00441-006-0308-z.
[30]
Sakaguchi, Y.; Sekiya, I.; Yagishita, K.; Yokoyama, A.; Koga, H.; Sekiya, I. Comparison of human stem cells derived from various mesenchymal tissues: Superiority of synovium as a cell source. Arthritis Rheum. 2005, 52, 2521–2529, doi:10.1002/art.21212.
[31]
De Bari, C.; Dell’Accio, F.; Tylzanowski, P.; Luyten, F.P. Multipotent mesenchymal stem cells from adult human synovial membrane. Arthritis Rheum. 2001, 44, 1928–1942, doi:10.1002/1529-0131(200108)44:8<1928::AID-ART331>3.0.CO;2-P.
[32]
Zuk, P.A.; Zhu, M.; Ashjian, P.; de Ugarte, D.A.; Huang, J.I.; Mizuno, H.; Alfonso, Z.C.; Fraser, J.K.; Benhaim, P.; Hedrick, M.H. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 2002, 13, 4279–4295, doi:10.1091/mbc.E02-02-0105.
[33]
Miura, M.; Gronthos, S.; Zhao, M.; Lu, B.; Fisher, L.W.; Robey, P.G.; Shi, S. SHED: Stem cells from human exfoliated deciduous teeth. PNAS 2003, 100, 5807–5812, doi:10.1073/pnas.0937635100.
[34]
Hernigou, P.H.; Poignard, A.; Beaujean, F.; Rouard, H. Percutaneous autologous bone-marrow grafting for nonunions. Influence of the number and concentration of progenitor cells. J. Bone Jt. Surg. 2005, 87, 1430–1437, doi:10.2106/JBJS.D.02215.
[35]
Hernigou, P.; Poignard, A.; Manicom, O.; Surgeon, O.; Mathieu, G.; Rouard, H. The use of percutaneous autologous bone marrow transplantation in nonunion and avascular necrosis of bone. J. Bone Jt. Surg. 2005, 87, 896–902.
Demirbag, B.; Huri, P.Y.; Kose, G.T.; Buyuksungur, A.; Hasirci, V. Advanced cell therapies with and without scaffolds. Biotechnol. J. 2011, 6, 1437–1453, doi:10.1002/biot.201100261.
[39]
Nakamura, A.; Akahane, M.; Shigematsu, H.; Tadokoro, M.; Morita, Y.; Ohgushic, H.; Dohi, Y.; Imamura, T.; Tanakaa, Y. Cell sheet transplantation of cultured mesenchymal stem cells enhances bone formation in a rat nonunion model. Bone 2010, 46, 418–424, doi:10.1016/j.bone.2009.08.048.
[40]
Bruder, S.P.; Kurth, A.A.; Shea, M.; Hayes, C.; Jaiswal, N.; Kadiyala, S. Bone regeneration by implantation of purified, culture-expanded human mesenchymal stem cells. J. Orthop. Res. 1998, 16, 155–162, doi:10.1002/jor.1100160202.
[41]
Bruder, S.P.; Kraus, K.H.; Goldberg, V.M.; Kadiyala, S. The effect of implants loaded with autologous mesenchymal stem cells on the healing of canine segmental bone defects. J. Bone Jt. Surg. 1998, 80, 985–996.
[42]
Bruder, S.P.; Jaiswal, N.; Ricalton, N.S.; Mosca, J.; Krauset, K.H.; Kadiyala, S. Mesenchymal stem cells in osteobiology and applied bone regeneration. Clin. Orthop. Relat. Res. 1998, 355, S247–S256.
[43]
Myeroff, C.; Archdeacon, M. Autogenous bone graft: Donor sites and techniques. J. Bone Jt. Surg. 2011, 93, 2227–2236, doi:10.2106/JBJS.J.01513.
[44]
Pape, H.C.; Evans, A.; Kobbe, P. Autologous bone graft: Properties and techniques. J. Orthop. Trauma 2010, 24, S36–S40, doi:10.1097/BOT.0b013e3181cec4a1.
[45]
Dimitriou, R.; Mataliotakis, G.I.; Angoules, A.G.; Kanakaris, N.K.; Giannoudis, P.V. Complications following autologous bone graft harvesting from the iliac crest and using the RIA: A systematic review. Injury 2011, 42, S3–S15.
[46]
Graham, S.M.; Leonidou, A.; Aslam-Pervez, N.; Hamza, A.; Panteliadis, P.; Heliotis, M.; Mantalaris, A.; Tsiridis, E. Biological therapy of bone defects: The immunology of bone allo-transplantation. Expert Opin. Biol. Ther. 2010, 10, 885–901, doi:10.1517/14712598.2010.481669.
[47]
Rihn, J.A.; Kirkpatrick, K.; Albert, T.J. Graft options in posterolateral and posterior interbody lumbar fusion. Spine 2010, 35, 1629–1639, doi:10.1097/BRS.0b013e3181d25803.
[48]
Gan, Y.; Dai, K.; Zhang, P.; Tang, T.; Zhu, Z.; Lu, J. The clinical use of enriched bone marrow stem cells combined with porous beta-tricalcium phosphate in posterior spinal fusion. Biomaterials 2008, 29, 3973–3982, doi:10.1016/j.biomaterials.2008.06.026.
[49]
Boden, S.D. Biology of lumbar spine fusion and use of bone graft substitutes: Present, future, and next generation. Tissue Eng. 2000, 6, 383–399, doi:10.1089/107632700418092.
[50]
Carraro, G.; Albertin, G.; Forneris, M.; Nussdorfer, G.G. Similar sequence-free amplification of human glyceraldehyde-3-phosphate dehydrogenase for real time RT-PCR applications. Mol. Cell. Probes 2005, 19, 181–186, doi:10.1016/j.mcp.2004.11.004.
[51]
Hoshiba, T.; Kawazoe, N.; Tateishi, T.; Chen, G. Development of stepwise osteogenesis-mimicking matrices for the regulation of mesenchymal stem cell functions. J. Biol. Chem. 2009, 284, 31164–31173, doi:10.1074/jbc.M109.054676.
[52]
Pattyn, F.; Speleman, F.; de Paepe, A.; Vandesompele, J. RTPrimerDB: The real-time PCR primer and probe database. Nucleic Acids Res. 2003, 31, 122–123, doi:10.1093/nar/gkg011.
[53]
Schaap-Oz87iemlak, A.M.; Raymakers, R.A.; Bergevoet, S.M.; Gilissen, C.; Jansen, B.J.H.; Adema, G.J.; K？gler, G.; le Sage, C.; Agami, R.; van der Reijden, B.A.; Jansen, J.H. MicroRNA hsa-miR-135b regulates mineralization in osteogenic differentiation of human unrestricted somatic stem cells. Stem Cells Dev. 2010, 19, 877–885, doi:10.1089/scd.2009.0112.
[54]
Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(？？？CT) method. Methods 2001, 25, 402–408, doi:10.1006/meth.2001.1262.
[55]
Krause, U.; Seckinger, A.; Gregory, C.A. Assays of osteogenic differentiation by cultured human mesenchymal stem cells. Methods Mol. Biol. 2011, 698, 215–230, doi:10.1007/978-1-60761-999-4_17.
[56]
Sampath, T.K.; Reddi, A.H. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiation. PNAS 1981, 78, 7599–7603, doi:10.1073/pnas.78.12.7599.
[57]
Reddi, A.H.; Huggins, C. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats. PNAS 1972, 69, 1601–1605, doi:10.1073/pnas.69.6.1601.
[58]
Russell, J.L.; Block, J.E. Clinical utility of demineralized bone matrix for osseous defects, arthrodesis, and reconstruction: Impact of processing techniques and study methodology. Orthopedics 1999, 22, 524–533.
[59]
Stenzel, K.H.; Miyata, T.; Rubin, A.L. Collagen as a biomaterial. Ann. Rev. Biophys. Bioeng. 1974, 3, 231–253, doi:10.1146/annurev.bb.03.060174.001311.
[60]
Miyata, T.; Taira, T.; Noishiki, Y. Collagen engineering for biomaterial use. Clin. Mater. 1992, 9, 139–148, doi:10.1016/0267-6605(92)90093-9.
[61]
Arnett, T.R. Extracellular pH regulates bone cell function. J. Nutr. 2008, 138, 415–418.
[62]
Valimaki, V.V.; Aro, H.T. Molecular basis for action of bioactive glasses as bone graft substitute. Scand. J. Surg. 2006, 95, 95–102.
[63]
Thomas, M.V.; Puleo, D.A.; Al-Sabbagh, M. Bioactive glass three decades on. J. Long Term Eff. Med. Implant. 2005, 15, 585–597, doi:10.1615/JLongTermEffMedImplants.v15.i6.20.
[64]
Tilocca, A.; Cormack, A.N. Modeling the water-bioglass interface by ab initio molecular dynamics simulations. ACS Appl. Mater. Interfaces 2009, 1, 1324–1333, doi:10.1021/am900198t.
[65]
Kasten, P.; Beyen, I.; Niemeyer, P.; Luginbühl, R.; Bohner, M.; Richter, W. Porosity and pore size of beta-tricalcium phosphate scaffold can influence protein production and osteogenic differentiation of human mesenchymal stem cells: An in vitro and in vivo study. Acta Biomater. 2008, 4, 1904–1915, doi:10.1016/j.actbio.2008.05.017.
[66]
Byrne, E.M.; Farrell, E.; McMahon, L.A.; Haugh, M.G.; O’Brien, F.J.; Campbell, V.A.; Prendergast, P.J.; O’Connell, B.C. Gene expression by marrow stromal cells in a porous collagen-glycosaminoglycan scaffold is affected by pore size and mechanical stimulation. J. Mater. Sci. 2008, 19, 3455–3463.
[67]
Dadsetan, M.; Hefferan, T.E.; Szatkowski, J.P.; Mishra, P.K.; Macura, S.I.; Lu, L.; Yaszemski, M.J. Effect of hydrogel porosity on marrow stromal cell phenotypic expression. Biomaterials 2008, 29, 2193–2202, doi:10.1016/j.biomaterials.2008.01.006.
[68]
Long, F. Building strong bones: Molecular regulation of the osteoblast lineage. Nat. Rev. Mol. Cell Biol 2012, 13, 27–38, doi:10.1038/nrm3254.
[69]
Huggins, C.; Wiseman, S.; Reddi, A.H. Transformation of fibroblasts by allogeneic and xenogeneic transplants of demineralized tooth and bone. J. Exp. Med. 1970, 132, 1250–1258, doi:10.1084/jem.132.6.1250.
[70]
Lindholm, T.S.; Nilsson, O.S.; Lindholm, T.C. Extraskeletal and intraskeletal new bone formation induced by demineralized bone matrix combined with bone marrow cells. Clin. Orthop. Relat. Res. 1982, 171, 251–255.
[71]
McLaughlin, R.E.; Reger, S.I.; Bolander, M.; Eschenroeder, H.C. Enhancement of bone ingrowth by the use of bone matrix as a biologic cement. Clin. Orthop. Relat. Res. 1984, 183, 255–261.
[72]
Lee, K.J.; Roper, J.G.; Wang, J.C. Demineralized bone matrix and spinal arthrodesis. Spine 2005, 5, 217–223, doi:10.1016/j.spinee.2004.08.002.
[73]
Pacaccio, D.J.; Stern, S.F. Demineralized bone matrix: Basic science and clinical applications. Clin. Podiatric. Med. Surg. 2005, 22, 599–606, doi:10.1016/j.cpm.2005.07.001.
